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COMBINED ACTIVE HUMORAL AND CELLULAR IMMUNIZATION APPROACHES FOR 
THE TREATMENT OF SYNUCLEONOPATHIES 
 
Edward Rockenstein1, Gary Ostroff2, Fusun Dikengil3, Florentina Rus2, Michael Mante1, Jazmin 
Florio1, Anthony Adame1, Ivy Trinh1, Cassia Overk1, Eliezer Masliah1 and Robert Rissman1 
1Department of Neurosciences, University of California, San Diego, La Jolla, CA; 2Program in 
Molecular Medicine, and 3Internal Medicine, University of Massachusetts Medical School 
 
Objectives: Parkinson’s Disease (PD), Dementia with Lewy bodies (DLB), and Multiple System 
Atrophy (MSA) are neurodegenerative disorders of the aging population characterized by the 
progressive accumulation of alpha-synuclein. Jointly these disorders have been denominated 
synucleinopathies and currently no disease modifying treatments are available. Previous in vivo 
studies in transgenic (tg) mice have shown that active and passive immunization targeting 
alpha-synuclein ameliorates to some extent deficits and synuclein accumulation, however it’s 
unknown if combining humoral and cellular immunization might synergize and also reduce 
inflammation and improve microglial cell mediated synuclein clearance.   
 
Methods: PDGF- alpha-synuclein tg mice and control non-tg mice were immunized with: 1) 
Glucan Particle (GP) adjuvant alone, 2) GP human (hu)- alpha-synuclein (active immunization), 
3) GP plus rapamycin and 4) GP plus rapamycin and hu-alpha-synuclein (combined active and 
humoral) and analyzed by neuropathological and biochemical markers. 
 
Results: Compared to tg mice treated with adjuvant alone, mice immunized with GP hu-alpha-
synuclein displayed a 30% reduction in alpha-synuclein accumulation. Combined 
immunotherapy with GP plus rapamycin and hu-alpha-synuclein resulted in 50% reduction in 
alpha-synuclein accumulation which was accompanied by reduced neuro-inflammation (Iba-1, 
GFAP, IL6, TNFalpha), phospho and insoluble alpha-synuclein, microglia and astroglia cell 
numbers, and retention of CD25, FoxP3 and CD4 positive cells. Levels of TGFb1 were also 
increased. Serological studies showed that active immunization resulted in higher levels of total 
IgG, IgG1 and IgG2 titers, levels were slightly higher in the combined group. 
 
Conclusions: In vivo studies targeting alpha-synuclein support the hypothesis that cellular 
immunization might enhance the effects of active immunotherapy for the treatment of 
synucleionopathies.  
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